• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TBPH

TBPH

Theravance Biopharma, Inc.

NASDAQHealthcareBiotechnologyKY

USD15.92

+0.34 (+2.18%)

Rating:A-

Company Profile

CEO

Rick E. Winningham

IPO Date

2014-05-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

KY

Market Metrics

Open

$15.65

Prev. Close

$15.58

Day Low

$15.65

Day High

$16.18

52W Low

$10.42

52W High

$21.03

Market Cap

$0.82B

Volume

0.33M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

24.5%

Avg Negative

17.1%

Avg Neutral

58.3%

News Feed

Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021

PRNewsWire·7/20/2021·↑ positive

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares

PRNewsWire·6/24/2021·↑ positive

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares

PRNewsWire·6/24/2021·↑ positive

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

Zacks Investment Research·6/22/2021·↓ negative

Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study

Benzinga·6/21/2021·↑ positive

Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19

PRNewsWire·6/21/2021·↑ positive

Theravance Biopharma to Participate in an Upcoming Investor Conference

PRNewsWire·5/6/2021·↑ positive

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

Zacks Investment Research·5/5/2021·↓ negative

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/4/2021·↓ negative

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/4/2021·↑ positive